Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Tables)

v3.21.1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2021
Segment Information  
Schedule of Segment Information

The Company operates in two reportable segments, Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development. The accounting policies of the Company’s segments are the same as those described in Note 2. The following tables summarize, for the periods indicated, operating results from continued operations by reportable segment:

Pharmaceutical

    

and

($ in thousands)

Dermatology

Biotechnology

Products

Product

Three Months Ended March 31, 2021

    

Sales

    

Development

    

Consolidated

Net revenue

$

10,719

$

868

$

11,587

Direct cost of goods

 

(3,908)

 

 

(3,908)

Sales and marketing costs

 

(5,070)

 

 

(5,070)

Research and development

 

 

(20,154)

 

(20,154)

General and administrative

(1,156)

(11,316)

(12,472)

Other expense

 

(221)

 

4,172

 

3,951

Segment income (loss)

$

364

(26,430)

$

(26,066)

Segment assets

Intangible assets, net

14,442

14,442

Tangible assets

42,200

334,401

376,601

Total segment assets

$

56,642

$

334,401

$

391,043

Pharmaceutical

and

Dermatology

Biotechnology

($ in thousands)

Products

Product

Three Months Ended March 31, 2020

    

Sales

    

Development

    

Consolidated

Net revenue

$

11,946

$

972

$

12,918

Direct cost of goods

 

(3,810)

 

(3,810)

Sales and marketing costs

 

(4,679)

 

(4,679)

Research and development

 

 

(15,117)

(15,117)

General and administrative

 

(953)

 

(9,887)

(10,840)

Other expense

(207)

(2,333)

(2,540)

Segment income (loss)

$

2,297

$

(26,365)

$

(24,068)

Segment assets

Intangible assets, net

7,022

7,022

Tangible assets

23,550

198,187

221,737

Total segment assets

$

30,572

$

198,187

$

228,759